When we think of cell therapies, we almost immediately think of immunotherapies for cancer or other deadly diseases. But there are myriad indications where cell therapy solutions could make major improvements to a patient's quality of life. Take for example muscle degeneration, where conditions such as urinary incontinence affect millions of people (especially as we age) resulting in a poor quality of life, social stigma, and may even impact our mental health.

MUVON Therapeutics is developing an autologous cell therapy for the treatment of diseases related to skeletal muscle damage or degradation. Their goal is to offer the patients in need minimally invasive, low-risk treatments for the regeneration of skeletal muscle tissue, to help them regain control over their life.

MUVON Therapeutics is a Life Science Spin-off from the University of Zurich and is co-funded by the Horizon 2020 programme.